Loading...

Neogen Corporation Peer Comparison

Metric Value Ranking
Market Cap $2.2 Billion 9/15 IQV
$35.9B
ICLR
$15.4B
MEDP
$10.5B
QGEN
$8.7B
RDNT
$4.6B
SYNH
$4.5B
SHC
$3.9B
OLK
$3.2B
NEOG
$2.2B
MYGN
$1.2B
ACRS
$232.2M
SERA
$140.7M
FONR
$101.6M
XGN
$84.5M
BNR
$64.1M
Gross Margin 49% 10/15 RDNT
100%
ACRS
85%
BNR
71%
MYGN
70%
QGEN
61%
OLK
61%
XGN
56%
SHC
55%
SERA
55%
NEOG
49%
FONR
40%
IQV
35%
ICLR
25%
SYNH
22%
MEDP
-38%
Profit Margin -100% 13/15 QGEN
20%
MEDP
18%
FONR
13%
IQV
11%
ICLR
10%
SHC
6%
RDNT
5%
SYNH
0%
MYGN
-10%
BNR
-28%
XGN
-40%
OLK
-56%
NEOG
-100%
ACRS
-100%
SERA
-100%
EBITDA margin -198% 13/15 MEDP
118%
RDNT
93%
SHC
43%
QGEN
35%
FONR
29%
IQV
26%
ICLR
19%
SYNH
8%
MYGN
-1%
BNR
-30%
XGN
-37%
OLK
-73%
NEOG
-198%
ACRS
-241%
SERA
-30559%
Quarterly Revenue $231.3 Million 8/15 IQV
$4.0B
ICLR
$2.0B
SYNH
$1.4B
MEDP
$533.3M
QGEN
$501.9M
RDNT
$461.1M
SHC
$285.5M
NEOG
$231.3M
MYGN
$213.3M
BNR
$29.6M
OLK
$28.6M
FONR
$25.0M
XGN
$12.5M
ACRS
$4.3M
SERA
$29,000
Quarterly Earnings -$456.3 Million 15/15 IQV
$437.0M
ICLR
$197.1M
QGEN
$98.1M
MEDP
$96.5M
RDNT
$20.9M
SHC
$17.0M
FONR
$3.1M
SYNH
$793,000
XGN
-$5.0M
ACRS
-$7.6M
SERA
-$7.9M
BNR
-$8.2M
OLK
-$16.0M
MYGN
-$22.1M
NEOG
-$456.3M
Quarterly Free Cash Flow $78.7 Million 5/15 ICLR
$370.1M
MEDP
$167.4M
RDNT
$161.5M
QGEN
$138.0M
NEOG
$78.7M
SHC
$59.2M
ACRS
$22.0M
FONR
-$148,000
XGN
-$2.3M
MYGN
-$5.6M
SERA
-$6.3M
BNR
-$7.0M
OLK
-$8.2M
SYNH
-$51.6M
IQV
-$0
Trailing 4 Quarters Revenue $913.8 Million 9/15 FONR
$102.9B
IQV
$15.4B
ICLR
$6.2B
SYNH
$5.4B
MEDP
$2.1B
QGEN
$2.0B
RDNT
$1.8B
SHC
$1.1B
NEOG
$913.8M
MYGN
$823.6M
OLK
$171.4M
BNR
$117.7M
XGN
$55.8M
ACRS
$27.1M
SERA
$94,000
Trailing 4 Quarters Earnings -$476.3 Million 15/15 IQV
$4.0B
ICLR
$2.0B
SYNH
$1.4B
MEDP
$533.3M
QGEN
$501.9M
RDNT
$461.1M
SHC
$285.5M
NEOG
$231.3M
MYGN
$213.3M
BNR
$29.6M
OLK
$28.6M
FONR
$25.0M
XGN
$12.5M
ACRS
$4.3M
SERA
$29,000
Quarterly Earnings Growth -12985% 15/15 RDNT
217879%
SHC
224%
BNR
80%
ACRS
74%
MYGN
64%
MEDP
37%
QGEN
26%
ICLR
20%
XGN
7%
IQV
-7%
SERA
-10%
OLK
-14%
FONR
-64%
SYNH
-99%
NEOG
-12985%
Annual Earnings Growth -46707% 15/15 FONR
196749%
RDNT
102%
MYGN
72%
ACRS
69%
MEDP
44%
BNR
25%
SHC
24%
XGN
17%
SERA
17%
ICLR
4%
IQV
0%
SYNH
-67%
QGEN
-71%
OLK
-1544%
NEOG
-46707%
Quarterly Revenue Growth 1% 9/15 RDNT
461042%
FONR
1134%
MYGN
11%
MEDP
8%
SHC
8%
QGEN
5%
OLK
4%
IQV
2%
NEOG
1%
BNR
1%
SYNH
0%
ICLR
-1%
XGN
-7%
SERA
-31%
ACRS
-53%
Annual Revenue Growth 0% 9/15 FONR
129585%
ACRS
82%
RDNT
46%
MYGN
11%
MEDP
10%
SHC
9%
IQV
2%
SYNH
1%
NEOG
0%
QGEN
0%
XGN
0%
BNR
-10%
OLK
-15%
ICLR
-23%
SERA
-77%
Cash On Hand $140.2 Million 7/15 IQV
$1.7B
QGEN
$973.0M
RDNT
$748.9M
ICLR
$695.5M
MEDP
$656.9M
SHC
$306.7M
NEOG
$140.2M
BNR
$114.7M
OLK
$109.3M
MYGN
$99.9M
SYNH
$82.2M
FONR
$54.2M
ACRS
$47.7M
XGN
$22.0M
SERA
$2.7M
Short Term Debt $2.6 Million 11/15 IQV
$1.1B
QGEN
$555.3M
RDNT
$82.1M
SYNH
$68.3M
ICLR
$29.8M
SHC
$22.9M
MYGN
$13.5M
FONR
$7.6M
BNR
$6.4M
OLK
$4.1M
NEOG
$2.6M
XGN
$1.5M
SERA
$305,000
ACRS
-$0
MEDP
-$670.9M
Long Term Debt $889.9 Million 6/15 ICLR
$3.4B
SYNH
$2.8B
SHC
$2.3B
RDNT
$1.7B
QGEN
$1.4B
NEOG
$889.9M
IQV
$173.0M
MYGN
$129.6M
MEDP
$128.3M
FONR
$37.4M
OLK
$22.1M
XGN
$21.8M
BNR
$16.8M
SERA
$168,000
ACRS
$0
PE -1.00 9/15 QGEN
94.02
RDNT
90.38
SYNH
62.59
SHC
54.81
ICLR
28.98
MEDP
28.60
IQV
26.15
FONR
0.00
NEOG
-1.00
MYGN
-1.00
ACRS
-1.00
XGN
-1.00
BNR
-1.00
OLK
-1.00
SERA
-1.00
PS 2.36 9/15 SERA
1497.15
OLK
18.91
ACRS
8.58
MEDP
5.05
QGEN
4.44
SHC
3.46
RDNT
2.59
ICLR
2.47
NEOG
2.36
BNR
2.36
IQV
2.33
XGN
1.52
MYGN
1.45
SYNH
0.82
FONR
0.00
PB 0.81 13/15 MEDP
11.86
SHC
8.25
OLK
7.03
XGN
6.57
IQV
5.92
RDNT
4.10
SERA
2.58
QGEN
2.48
ACRS
1.78
MYGN
1.63
ICLR
1.58
SYNH
1.28
NEOG
0.81
FONR
0.64
BNR
0.43
PC 15.39 7/15 SYNH
54.25
SERA
52.43
OLK
29.67
ICLR
22.14
IQV
21.10
MEDP
15.92
NEOG
15.39
SHC
12.64
MYGN
11.93
QGEN
8.98
RDNT
6.13
ACRS
4.87
XGN
3.83
FONR
1.87
BNR
0.56
Liabilities to Equity 0.52 9/15 SHC
5.70
IQV
3.43
RDNT
2.41
XGN
2.39
MEDP
1.36
SYNH
1.31
QGEN
0.78
ICLR
0.76
NEOG
0.52
BNR
0.52
MYGN
0.48
SERA
0.45
ACRS
0.40
FONR
0.32
OLK
0.18
ROA -0.12 12/15 FONR
11508%
MEDP
18%
IQV
5%
ICLR
3%
RDNT
2%
SHC
2%
SYNH
1%
QGEN
1%
OLK
-6%
BNR
-10%
MYGN
-11%
NEOG
-12%
ACRS
-20%
XGN
-39%
SERA
-41%
ROE -0.18 12/15 FONR
14482%
MEDP
41%
IQV
23%
SHC
15%
RDNT
6%
ICLR
5%
QGEN
3%
SYNH
2%
OLK
-7%
BNR
-15%
MYGN
-16%
NEOG
-18%
ACRS
-28%
SERA
-59%
XGN
-132%
Current Ratio 2.93 6/15 OLK
6.68
FONR
3.97
ACRS
3.49
SERA
3.24
MYGN
3.09
NEOG
2.93
BNR
2.93
ICLR
2.31
QGEN
2.29
SYNH
1.76
MEDP
1.73
RDNT
1.52
XGN
1.42
IQV
1.29
SHC
1.18
Quick Ratio 0.10 12/15 QGEN
94.02
RDNT
90.38
SYNH
62.59
SHC
54.81
ICLR
28.98
MEDP
28.60
IQV
26.15
FONR
0.00
NEOG
-1.00
MYGN
-1.00
ACRS
-1.00
XGN
-1.00
BNR
-1.00
OLK
-1.00
SERA
-1.00
Long Term Debt to Equity 0.33 7/15 SHC}
4.97
RDNT}
1.85
XGN}
1.69
SYNH}
0.81
QGEN}
0.39
ICLR}
0.35
NEOG}
0.33
FONR}
0.22
MYGN}
0.18
MEDP}
0.15
BNR}
0.11
OLK}
0.05
IQV}
0.03
ACRS}
0.00
SERA}
0.00
Debt to Equity 0.33 7/15 SHC
5.01
RDNT
1.94
XGN
1.81
SYNH
0.83
QGEN
0.54
ICLR
0.35
NEOG
0.33
FONR
0.24
IQV
0.22
MYGN
0.20
BNR
0.16
MEDP
0.15
OLK
0.06
SERA
0.01
ACRS
0.00
Burn Rate 0.28 12/15 FONR
214.93
BNR
27.48
RDNT
11.38
QGEN
10.21
ACRS
6.28
OLK
6.11
SHC
3.74
XGN
3.51
MYGN
3.26
SYNH
0.64
SERA
0.34
NEOG
0.28
MEDP
-2.54
IQV
-11.83
ICLR
-12.98
Cash to Cap 0.06 9/15 BNR
1.79
FONR
0.53
XGN
0.26
ACRS
0.21
RDNT
0.16
QGEN
0.11
MYGN
0.08
SHC
0.08
NEOG
0.06
MEDP
0.06
IQV
0.05
ICLR
0.05
OLK
0.03
SYNH
0.02
SERA
0.02
CCR -0.17 12/15 RDNT
7.72
SHC
3.48
ICLR
1.88
MEDP
1.74
QGEN
1.41
BNR
0.85
SERA
0.80
OLK
0.52
XGN
0.46
MYGN
0.25
FONR
-0.05
NEOG
-0.17
ACRS
-2.90
SYNH
-65.12
IQV
EV to EBITDA -6.36 10/15 SYNH}
64.31
QGEN}
54.43
SHC}
48.26
ICLR}
46.34
IQV}
34.72
MEDP}
15.84
RDNT}
13.05
FONR}
12.05
BNR}
9.91
NEOG}
-6.36
SERA}
-15.63
ACRS}
-17.63
XGN}
-18.38
OLK}
-151.26
MYGN}
-561.30
EV to Revenue 3.19 7/15 SERA
1473.63
OLK
18.43
ACRS
6.82
SHC
5.29
QGEN
4.93
MEDP
4.79
NEOG
3.19
RDNT
3.15
ICLR
2.91
IQV
2.31
XGN
1.54
MYGN
1.50
SYNH
1.34
FONR
0.00
BNR
-3.25